Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04441528
Other study ID # IRB2021
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 1, 2018
Est. completion date November 1, 2019

Study information

Verified date June 2020
Source Istanbul University-Cerrahpasa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy of lid wipes containing terpinen-4-ol and sodium hyaluronate (Hy-ter®) for the treatment of seborrheic blepharitis compared to baby shampoo.


Description:

After being informed about the study and potential risks, all patients giving written consent will have a complete ophthalmological examination to determine eligibilty for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double blind manner (participant and investigator) in a 1:1 ratio to lid wipes containing terpinen-4-ol and sodium hyaluronate (Hy-terĀ®) or baby shampoo (twice daily).


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date November 1, 2019
Est. primary completion date November 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of seborrheic blepharitis

Exclusion Criteria:

- Patients with ophthalmological pathologies that may affect the tear film functions including ocular rosacea, contact lens use, history of any ocular surgery, or patients with systemic pathologies or those using systemic medications that may affect the tear film functions

- Patients younger than 18-year-old

- Patients who used any treatment for blepharitis within the 6 months prior to the examination

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lid wipes containing terpinen-4-ol and sodium hyaluronate
Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
Baby shampoo
Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.

Locations

Country Name City State
Turkey Istanbul University-Cerrahpasa Istanbul

Sponsors (2)

Lead Sponsor Collaborator
Istanbul University-Cerrahpasa Koç University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of the treatment assessed by the change in Blepharitis Symptom measure (BLISS) score BLISS score is calculated according to the answers given to the questionnaire. Higher BLISS scores is related to a worse outcome. (Range is between 0 and 39) 0-4-8-12 weeks
Secondary Efficacy of the treatment assessed by the change in Demodex mite count by light microscopy The number of mites in the epilated 4 eyelashes will be counted under microscope. 0-4-8-12 weeks
Secondary Efficacy of the treatment assessed by the change in the Schirmer test results Dry eye evaluation will be made with Schirmer test. 0-4-8-12 weeks
Secondary Efficacy of the treatment assessed by the change in the tear breakup time Dry eye evaluation will be made with tear breakup time. 0-4-8-12 weeks
Secondary Efficacy of the treatment assessed by the change in the ocular surface disease index score OSDI scores are calculated according to the responses to the questionnaire. Higher values are related to a worse outcome (range is between 0-100) 0-4-8-12 weeks
Secondary Efficacy of the treatment assessed by the change in the non-invasive tear breakup time Dry eye evaluation will be made with non-invasive tear breakup time. 0-4-8-12 weeks
Secondary Efficacy of the treatment assessed by the change in the meibomian gland loss Meibomian gland loss will be evaluated using anterior segment analysis system. 0-4-8-12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04678531 - TTO Swabs Versus Baby Shampoo in Patients With Seborrehic Blepharitis Phase 4